Alchemab Therapeutics Kicks Off Phase 1 Clinical Trial of ATLX-1282
Alchemab Therapeutics has proudly announced the start of a Phase 1 first-in-human clinical trial for ATLX-1282. This advancement comes on the heels of successful pre-clinical activities that were part of a licensing agreement with a major player in the industry. The excitement surrounding this trial underscores Alchemab's commitment to pioneering therapeutic solutions derived from naturally occurring antibodies in resilient individuals.
Major Financing Round to Propel Development
Alongside the initiation of the clinical trial, Alchemab also revealed a substantial Series A financing extension, now totaling an impressive amount. Notably, this funding round saw participation from prominent investors including Eli Lilly and Company, demonstrating their confidence in Alchemab's innovative platform.
Transformative Drug Discovery Platform
The company's proprietary platform utilizes AI technology to revolutionize drug discovery. By focusing on protective auto-antibodies, Alchemab is able to identify novel targets that leverage the immune system's potential. Their impressive database, known as the DataCube, houses over 6,000 curated patient samples, showcasing the power of their collaborative efforts across various health conditions.
Future Programs and Strategic Goals
With the additional capital raised from the financing round, Alchemab plans to advance ATLX-2847—a groundbreaking program targeting muscle atrophy. This initiative is indicative of Alchemab's broader aim to explore immune and neurological conditions, paving the way for cutting-edge treatments. Furthermore, the capital allows for continued enhancement of their AI-enabled platform.
Comments from Leadership
The response from leadership regarding the financing and clinical trials has been overwhelmingly positive. Kate Bingham, Alchemab's Chair, expressed her enthusiasm about the company's trajectory and welcomed new investors who align with their vision of novel drug discovery. She highlighted the importance of these developments for the future of Alchemab.
Similarly, Jane Osbourn, Co-Founder and Chief Executive Officer, emphasized the significance of reaching critical milestones in their drug development journey and hopes for swift progression in bringing transformative therapies to patients. Mike Hutton, Senior Vice President at Eli Lilly, echoed this excitement, anticipating meaningful results from the collaboration between the two companies.
About Alchemab Therapeutics
Founded in 2019, Alchemab is dedicated to studying the immune responses of individuals who exhibit resistance to various diseases. Their unique approach involves isolating antibodies that are prevalent in these resilient groups while absent in individuals affected by disease progression. The ultimate goal is to unlock the mechanisms of wellness and develop innovative treatments for conditions lacking effective interventions.
Frequently Asked Questions
What is ATLX-1282?
ATLX-1282 is Alchemab Therapeutics' drug candidate, currently in Phase 1 clinical trials aimed at exploring its safety and efficacy in humans.
Who is financing Alchemab's developments?
The recent Series A financing round was supported by Eli Lilly and Company, alongside other esteemed investors, enhancing Alchemab's resources for further developments.
How does Alchemab's platform work?
Alchemab's AI-enabled platform identifies protective auto-antibodies and novel targets to aid in drug discovery, utilizing an extensive database of patient-derived immune responses.
What are the future goals for Alchemab?
Alchemab aims to advance multiple drug candidates targeting immune and neurological conditions while continually enhancing their innovative drug discovery platform.
When was Alchemab established?
Alchemab Therapeutics was founded in 2019 and is headquartered in London, with additional labs in Cambridge.
